Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Recent studies indicate that selective noradrenergic (atomoxetine) and serotonergic (citalopram) reuptake inhibitors may improve response inhibition in selected patients with Parkinson's disease, restoring behavioral performance and brain activity. We reassessed the behavioral efficacy of these drugs in a larger cohort and developed predictive models to identify patient responders. We used a double‐blind randomized three‐way crossover design to investigate stopping efficiency in 34 patients with idiopathic Parkinson's disease after 40 mg atomoxetine, 30 mg citalopram, or placebo. Diffusion‐weighted and functional imaging measured microstructural properties and regional brain activations, respectively. We confirmed that Parkinson's disease impairs response inhibition. Overall, drug effects on response inhibition varied substantially across patients at both behavioral and brain activity levels. We therefore built binary classifiers with leave‐one‐out cross‐validation (LOOCV) to predict patients’ responses in terms of improved stopping efficiency. We identified two optimal models: (1) a “clinical” model that predicted the response of an individual patient with 77–79% accuracy for atomoxetine and citalopram, using clinically available information including age, cognitive status, and levodopa equivalent dose, and a simple diffusion‐weighted imaging scan; and (2) a “mechanistic” model that explained the behavioral response with 85% accuracy for each drug, using drug‐induced changes of brain activations in the striatum and presupplementary motor area from functional imaging. These data support growing evidence for the role of noradrenaline and serotonin in inhibitory control. Although noradrenergic and serotonergic drugs have highly variable effects in patients with Parkinson's disease, the individual patient's response to each drug can be predicted using a pattern of clinical and neuroimaging features. Hum Brain Mapp 37:1026–1037, 2016. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573
Self-citationEagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548 · cited 3×
“In contrast, animal and human studies indicate noradrenergic and serotonergic regulation of response inhibition [Aston-Jones and Cohen, 2005; Eagle et al., 2008; Robbins, 2007].”
BackgroundResultSelf-citationRobbins, T. W. (2007) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2007.2097 · Cited by 413 · cited 5×
“…with common frontostriatal circuits [Chamberlain et al., 2009; Del-Ben et al., 2005; Macoveanu et al., 2013], we suggest that the distinct clinical models for atomoxotine and citalopram reflect different roles of noradrenaline and serotonin in inhibitory control [Eagle et al., 2008; Robbins, 2007].”
BackgroundMethodResultInfluentialSelf-citationVerbruggen, F., Chambers, C. D., & Logan, G. D. (2013) · Psychological Science · doi:10.1177/0956797612457390 · Cited by 386
Robinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301487 · Cited by 359 · cited 1×
“However, the behavioral effects of atomoxetine and citalopram depend on individual differences in the baseline state of noradrenergic and serotonergic systems [Robinson et al., 2008; Ye et al., 2014, 2015] which may be one reason why unstratified studies yield negative results.”
BackgroundSelf-citationInhibition of ongoing responses in patients with Parkinson's disease
Gauggel, S., Rieger, M., & Feghoff, T.-A. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.016469 · Cited by 284 · cited 1×
“Response inhibition has been widely studied using the stop-signal reaction time (SSRT) task in Parkinson’s disease and other brain disorders [Cubillo et al., 2014a; Gauggel et al., 2004; Luijten et al., 2013; Obeso et al., 2011a; Verbruggen et al., 2013].”
MethodDel-Ben, C. M., Deakin, J. F. W., Mckie, S., Delvai, N. A., Williams, S. R., Elliott, R., Dolan, M., & Anderson, I. M. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300728 · Cited by 260 · cited 2×
“Although the effects of both drugs are associated with common frontostriatal circuits [Chamberlain et al., 2009; Del-Ben et al., 2005; Macoveanu et al., 2013], we suggest that the distinct clinical models for atomoxotine and citalopram reflect different roles of noradrenaline and serotonin in inhibitory control [Eagle…”
BackgroundStratified medicine for mental disorders
Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.010 · Cited by 186
Self-citation
Cited by
Building better biomarkers: brain models in translational neuroimaging
Woo, C.-W., Chang, L. J., Lindquist, M. A., & Wager, T. D. (2017) · Nature Neuroscience · doi:10.1038/nn.4478 · Cited by 1,056
Machine learning in mental health: a scoping review of methods and applications
Shatte, A. B. R., Hutchinson, D. M., & Teague, S. J. (2019) · Psychological Medicine · doi:10.1017/s0033291719000151 · Cited by 1,047
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia
Hughes, L. E., Rittman, T., Robbins, T. W., & Rowe, J. B. (2018) · Brain · doi:10.1093/brain/awy176 · Cited by 81
Self-citationDeficits in neurite density underlie white matter structure abnormalities in first-episode psychosis
Rae, C. L., Davies, G., Garfinkel, S. N., Gabel, M. C., Dowell, N. G., Cercignani, M., Seth, A. K., Greenwood, K. E., Medford, N., & Critchley, H. D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.008 · Cited by 65
“These permit detailed characterisation of white matter integrity that can shed light on the aetiology of brain disorders, and provide indicators for diagnosis, treatment response, and prognosis (14, 22, 23).”
BackgroundSelf-citation
Metadata
- Authors
- Ye, Z., Rae, C. L., Nombela, C., Ham, T., Rittman, T., Jones, P. S., Rodríguez, P. V., Coyle‐Gilchrist, I., Regenthal, R., Altena, E., Housden, C. R., Maxwell, H., Sahakian, B. J., Barker, R. A., Robbins, T. W., & Rowe, J. B.
- Venue
- Human Brain Mapping
- Publisher
- Wiley
- Published
- 2016-01-12
- Volume
- 37
- Issue
- 3
- Pages
- 1026-1037
- ISSN
- 1065-9471 (ISSN-L)
- 1097-0193
- OpenAlex
- W2235686152
- Cited by
- 68
- References
- 14
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. https://app.cochat.ai/papers/10.1002/hbm.23087
- The paper
- Ye, Z., Rae, C. L., Nombela, C., Ham, T., Rittman, T., Jones, P. S., Rodríguez, P. V., Coyle‐Gilchrist, I., Regenthal, R., Altena, E., Housden, C. R., Maxwell, H., Sahakian, B. J., Barker, R. A., Robbins, T. W., & Rowe, J. B. (2016). Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Human Brain Mapping. https://doi.org/10.1002/hbm.23087
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.